Capnia Inc.

Capnia Inc.

Capnia Inc. was founded to commercialize CO2-based sensor technology derived from academic research. The company's primary focus is on developing medical devices that measure blood flow in real-time, addressing conditions such as stroke, traumatic brain injury, and other vascular disorders. Wealth origin is not publicly disclosed, and no founding principal has been named in available public records. The firm's strategy centers on proprietary CO2 sensing platforms, which it applies to diagnostic and therapeutic applications. It primarily targets the clinical neurology and critical care markets. Capnia has not disclosed specific portfolio companies, deals, or co-investors; its geographic footprint includes offices in the United States (Palo Alto, San Diego, Redwood City, Carlsbad, San Francisco, Denver) and Norway (Oslo), with a registered address in Kowloon, Hong Kong. Total deployment, team size, and the firm's exact number of professionals are not publicly available. No adjacent vehicles or dated operational events from the last 24 months have been confirmed. The firm appears to maintain a lean research-and-development posture without disclosed philanthropic structures. Capnia's structural differentiator lies in its reliance on CO2 sensor technology patented through university partnerships, rather than a traditional investment vehicle or family office model. The firm's limited public disclosure suggests a small-scale operation focused on product development rather than capital deployment.